Person profile

Public information reviewed

Eric Easom

Role

President, Chief Executive Officer and Board Chair at AN2 Therapeutics, Inc. (NASDAQ: ANTX)

Board role

President, Chief Executive Officer and Board Chair · AN2 Therapeutics, Inc. (NASDAQ: ANTX)

AN2 Therapeutics, Inc. (NASDAQ: ANTX)

President, Chief Executive Officer and Board Chair · Current mandate

Executive
FollowSave PDF
More
Reports & analysisAlpha Eval
Public sources
3 reviewed
Profile ownership
Not yet claimed
Last reviewed
Sep 5, 2026
View sources

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
21 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Alpha has not published a narrative summary because the current public source set is not sufficient.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

President, Chief Executive Officer and Board Chair

AN2 Therapeutics, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

AN2 Therapeutics, Inc.

Open AN2 Therapeutics, Inc. profile →

President, Chief Executive Officer and Board Chair at AN2 Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-16

President, Chief Executive Officer and Board Chair at AN2 Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-16

AN2 Therapeutics, …AN2 Therapeutics, Inc.Eric Easom

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingANTX DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:eric-easom
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of AN2 Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at AN2 Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: President, Chief Executive Officer and Board Chair1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1880438/000119312526170314/antx-20260422.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 5, 2026

    Supports: President, Chief Executive Officer and Board Chair at AN2 Therapeutics, Inc. (NASDAQ: ANTX)

  3. https://www.sec.gov/Archives/edgar/data/1880438/000119312526170314/antx-20260422.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership